Novavax (NASDAQ: NVAX) reported Q2 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $14 million versus the consensus estimate of $9.9 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.